Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
Editas Medicine (Nasdaq: EDIT) announced a moderated digital poster presentation at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10, 2025. The poster, titled “A transformative LDL cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates”, is scheduled for Saturday, November 8, 10:45 a.m.–11:45 a.m. CT in the Basic Science Zone during the session Cutting-Edge Gene and Precision Therapies. Presenter: Anshul Gupta, Vice President, Preclinical Development. Final abstract number is 4364195. The accepted abstract is available on the AHA website and a copy of the poster will be posted in the company’s Posters & Presentations web section at the time of the presentation and remain accessible afterwards.
Editas Medicine (Nasdaq: EDIT) ha annunciato una presentazione poster digitale moderata ai American Heart Association Scientific Sessions 2025 a New Orleans, dal 7 al 10 novembre 2025. Il poster, intitolato “Una medicina di editing genico CRISPR in vivo che abbassa in modo trasformativo il colesterolo LDL e che funziona aumentando in modo funzionale LDLR nei topi e nelle primate non umane”, è previsto per sabato 8 novembre, 10:45–11:45 CT nell’Area Scienze di Base durante la sessione Geni all'avanguardia e terapie di precisione. Relatore: Anshul Gupta, Vice Presidente Sviluppo Preclinico. Il numero dell’abstract finale è 4364195. L’abstract accettato è disponibile sul sito AHA e una copia del poster sarà pubblicata nella sezione poster e presentazioni del sito dell’azienda al momento della presentazione e rimarrà accessibile successivamente.
Editas Medicine (Nasdaq: EDIT) anunció una presentación moderada de póster digital en la American Heart Association Scientific Sessions 2025 en Nueva Orleans, del 7 al 10 de noviembre de 2025. El póster, titulado “Una medicina de edición genética CRISPR in vivo que transforma la reducción del colesterol LDL y que funcionalmente regula LDLR en ratones y primates no humanos”, está programado para el sábado 8 de noviembre, de 10:45 a. m. a 11:45 a. m. CT en la Zona de Ciencias Básicas durante la sesión Terapias génicas y de precisión de vanguardia. Presentador: Anshul Gupta, Vicepresidente de Desarrollo Preclínico. El número del abstract final es 4364195. El abstract aceptado está disponible en el sitio web de AHA y se publicará una copia del póster en la sección Posters & Presentations del sitio de la empresa en el momento de la presentación y permanecerá accesible posteriormente.
Editas Medicine (나스닥: EDIT)은 뉴올리언스에서 열리는 American Heart Association Scientific Sessions 2025에서 디지털 포스터 발표를 진행한다고 발표했습니다. 기간은 2025년 11월 7일부터 11월 10일까지입니다. 포스터 제목은 “체내 CRISPR 유전 편집 의약품이 LDL 콜레스테롤을 변환적으로 낮추고 LDLR를 생리학적으로 상향 조절한다”이며, 11월 8일 토요일, 10:45–11:45 CT에 기본 과학 영역의 세션 최신 유전자 및 정밀 치료법에서 발표됩니다. 발표자는 Anshul Gupta, 선임 부사장, 전임상 개발입니다. 최종 초록 번호는 4364195입니다. 승인된 초록은 AHA 웹사이트에서 확인 가능하며 발표 시점에 회사의 Posters & Presentations 섹션에 포스터 사본이 게시되고 그 후에도 계속 열람할 수 있습니다.
Editas Medicine (Nasdaq: EDIT) a annoncé une présentation poster numérique modérée lors des American Heart Association Scientific Sessions 2025 à New Orleans, du 7 au 10 novembre 2025. Le poster, intitulé « Un médicament d’édition CRISPR in vivo qui abaisse de manière transformative le cholestérol LDL et qui régule fonctionnellement LDLR chez les souris et les primates non humains », est prévu pour le samedi 8 novembre, de 10h45 à 11h45 CT dans la zone des Sciences de base durant la session Traitements de pointe par édition génétique et précision. Intervenant : Anshul Gupta, Vice-président Développement Préclinique. Le numéro de l’abstract final est 4364195. L’abstract accepté est disponible sur le site de l’AHA et une copie de l’affiche sera publiée dans la section Posters & Presentations du site de l’entreprise au moment de la présentation et restera accessible par la suite.
Editas Medicine (Nasdaq: EDIT) hat eine moderierte digitale Posterpräsentation bei den American Heart Association Scientific Sessions 2025 in New Orleans angekündigt, vom 7. bis 10. November 2025. Das Poster mit dem Titel „Eine transformative LDL-Cholesterin-senkende In-vivo-CRISPR-Genom-Editierungsmittel, das funktionell LDLR bei Mäusen und nichtmenschlichen Primaten hochreguliert“ ist für Samstag, 8. November, 10:45–11:45 Uhr CT in der Area Basic Science während der Sitzung Gentechnologie und Präzisionstherapien auf dem neuesten Stand vorgesehen. Referent: Anshul Gupta, Vice President, Preclinical Development. Die endgültige Abstract-Nummer lautet 4364195. Der akzeptierte Abstract ist auf der AHA-Website verfügbar und eine Kopie des Posters wird zum Zeitpunkt der Präsentation im Bereich Posters & Presentations der Unternehmenswebsite veröffentlicht und danach weiterhin zugänglich bleiben.
Editas Medicine (المدرجة في ناسداك: EDIT) أعلنت عن عرض ملصق رقمي معتدل خلال American Heart Association Scientific Sessions 2025 في نيو أورلينز، من 7 إلى 10 نوفمبر 2025. الملصق، بعنوان “دواء تحرير جيني CRISPR داخل الكائن الحي يخفض كوليسترول LDL بشكل تحويلي ويزيد تنظيم LDLR وظيفياً في mice والفُقاريات غير البشرية”، من المقرر أن يُعرض في السبت، 8 نوفمبر، من 10:45 صباحاً حتى 11:45 صباحاً بتوقيت الوسط في منطقة العلوم الأساسية خلال الجلسة علاجات الجينوم والتقنيات الدقيقة المتطورة. المقدم: Anshul Gupta, نائب الرئيس، التطوير قبل السريري. رقم الملخص النهائي هو 4364195. الملخص المعتمد متاح على موقع AHA وسيتم نشر نسخة من الملصق في قسم Posters & Presentations على موقع الشركة في وقت العرض وستظل متاحة بعد ذلك.
- None.
- None.
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at the upcoming American Heart Association (AHA) Scientific Sessions 2025 to be held November 7-10 in New Orleans, Louisiana.
- American Heart Association (AHA) Scientific Sessions 2025
Title: A transformative LDL cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates
Session Date and Time: Saturday, November 8, 10:45 a.m. – 11:45 a.m. CT
Session Title: Cutting-Edge Gene and Precision Therapies
Presentation Room: Basic Science Zone
Presenter: Anshul Gupta, Vice President, Preclinical Development at Editas Medicine
Final Abstract Number: 4364195
The accepted abstract is available on the AHA website. A copy of the poster presentation will be made available on the “Posters & Presentations” section of the Company’s website at the time of the presentation and will remain accessible following the event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Investor and Media Contacts: ir@editasmed.com media@editasmed.com
FAQ
What will Editas Medicine (EDIT) present at AHA Scientific Sessions 2025 on November 8?
Who is presenting Editas Medicine’s AHA poster and what is their role at EDIT?
Where and when during AHA 2025 is the Editas poster shown (session and room)?
What is the final abstract number for Editas Medicine’s AHA 2025 poster (EDIT)?
Will the Editas Medicine poster be available online after the AHA presentation?
